Actively Recruiting
NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
Led by NOBO Medicine · Updated on 2026-01-30
9
Participants Needed
6
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL
CONDITIONS
Official Title
NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 19 to 80 years
- Voluntary written informed consent to participate
- Histologically confirmed follicular lymphoma, mantle cell lymphoma, or marginal zone lymphoma
- Relapsed or refractory disease after more than two prior lines of therapy
- Measurable disease based on Lugano classification
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- Adequate organ function
You will not qualify if you...
- Previous treatment with NB02 (poseltinib)
- Disease progression while on BTK inhibitor monotherapy or BTK inhibitor-containing regimen (except if discontinued due to adverse effects, economic, or social reasons)
- Unable to take oral medication
- Unable to comply with study and follow-up procedures
- Concurrent use of other investigational drugs or participation in another clinical trial within 4 weeks before study drug administration
- Previous treatment with any BTK inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib)
- Known active HIV, hepatitis C virus, or hepatitis B virus infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Chonnam National University Hwasun Hospital
Hwasun, South Korea
Actively Recruiting
2
Seoul National University Bundang Hospital
Seongnam, South Korea
Actively Recruiting
3
Catholic univ of Yeouido St Mary's Hospital
Seoul, South Korea
Actively Recruiting
4
Samsung Medical Center
Seoul, South Korea
Actively Recruiting
5
Seoul National University Hospital
Seoul, South Korea
Actively Recruiting
6
Ulsan University Hospital
Ulsan, South Korea
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here